Close Menu
Home » Confident of Market Turnaround, MDS Proteomics Plans IPO for 2002

Confident of Market Turnaround, MDS Proteomics Plans IPO for 2002

Dec 17, 2001
Premium

MDS Proteomics plans to go through with an initial public offering next year to acquire additional funding, the company’s new CFO said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

PLOS Papers on Prostate Cancer by Ancestry, Korean Liver Function Genetics, Vibrio Cholerae

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

Genomics for Viral Tracking

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

Even More Personalized Medicines

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

Plan for Alzheimer's

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.

Mar
31
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Proteomics & Protein Research

  1. IsoPlexis Demonstrates Expanded Cell Profiling Capabilities in Immunotherapy Study

    Premium

  2. Genetic Alterations in Breast Cancer Influence Tumor Ecosystems

  3. Bruker Preliminary Q4 Revenues Up 8 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.